Wegovy is semaglutide from Novo Nordisk, approved for weight management and heart risk reduction, while Mounjaro is tirzepatide from Eli Lilly, approved for type 2 diabetes and not for weight loss. Wegovy comes as a weekly pen or daily pill and costs $149 to $399 a month self-pay, while Mounjaro is a weekly injection with a $1,112.16 list price per 28 days. Medicare's $50 GLP-1 Bridge covers Wegovy but not Mounjaro.
- $149 to $299Wegovy pill, self-pay
- $199 to $399Wegovy pen, self-pay
- $25Wegovy, commercial insurance with savings offer
On this page
Prices at a glance
- Wegovy pill, self-pay$149 to $299
- Wegovy pen, self-pay$199 to $399
- Wegovy, commercial insurance with savings offer$25
- Wegovy, Medicare GLP-1 Bridge$50
- Mounjaro, list price per 28-day supply$1,112.16
- Mounjaro, commercial insurance that covers it, with Savings Card$25
- Mounjaro, commercial insurance that does not cover it, with Savings Card$499
Side by side
wegovy
- Wegovy pill, self-pay[1]$149 to $299$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg)
- Wegovy pen, self-pay[1]$199 to $399$199 for a new patient's first 2 fills through December 31, 2026; then $349; Wegovy HD $399
- Wegovy, commercial insurance with savings offer[1]$25Savings capped at $100 a month
- Wegovy, Medicare GLP-1 Bridge[4]$50
mounjaro
Prices are national ranges from the sources listed below. Your price depends on your provider, location and case; confirm the cost with your provider before treatment. How we get these prices
Wegovy vs Mounjaro side by side
| Wegovy | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide[5] | Tirzepatide[6] |
| Maker | Novo Nordisk[1] | Eli Lilly[2] |
| How it works | GLP-1 receptor agonist[5] | GIP and GLP-1 receptor agonist[6] |
| Forms and schedule | Weekly pen, or a daily tablet on an empty stomach[5] | Weekly injection: single-dose pen, vial or KwikPen[6] |
| Doses | Pen 0.25 mg rising every 4 weeks to 2.4 mg, up to 7.2 mg (Wegovy HD); pill 1.5 mg rising every 30 days to 25 mg[5] | 2.5 mg, raised by 2.5 mg after at least 4 weeks if needed; up to 15 mg in adults, 10 mg in children[6] |
| FDA-approved uses | Weight management in adults (and ages 12 and up for the pen); lowering heart attack, stroke and heart death risk in adults with heart disease and obesity or overweight; MASH liver disease (pen)[5] | Blood sugar control in adults and children 10 and older with type 2 diabetes; lowering heart attack, stroke and heart death risk in adults with type 2 diabetes at high risk[6] |
| Weight results | 14.9% at 68 weeks on 2.4 mg vs 2.4% on placebo (no diabetes); 9.6% vs 3.4% (type 2 diabetes)[5] | 12 pounds on 5 mg to 25 pounds on 15 mg in adults with type 2 diabetes, per Lilly[2] |
| Self-pay price | Pill $149 to $299; pen $199 to $399[1] | No posted self-pay price; list $1,112.16 per 28 days[2][3] |
| Medicare GLP-1 Bridge | $50 a month[4] | Not covered[4] |
Wegovy vs Mounjaro for weight loss
Wegovy is labeled for weight management; Mounjaro is labeled for type 2 diabetes, and Lilly states it is not a weight loss drug.[2][5][6] In Wegovy’s trials, adults without diabetes lost an average 14.9% at 68 weeks on 2.4 mg, adults with type 2 diabetes lost 9.6%, and adults with obesity on Wegovy HD 7.2 mg lost 18.8% at 72 weeks.[5] For Mounjaro, Lilly says adults with type 2 diabetes lost 12 to 25 pounds in its studies, depending on dose.[2]
No trial has compared Wegovy and Mounjaro as brands. SURMOUNT-5 compared their ingredients at weight management doses in adults with obesity and no diabetes, and found an average 20.2% weight loss on tirzepatide against 13.7% on semaglutide at 72 weeks; it was open label and funded by Eli Lilly.[7] Lilly’s weight management tirzepatide brand is Zepbound; see Mounjaro vs Zepbound and Wegovy vs Zepbound. Talk with a clinician about which fits your diagnosis.
Wegovy vs Mounjaro cost
- Wegovy, cash: the pill is $149 for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg. The pen is $199 for each of a new patient’s first two fills through December 31, 2026, then $349, and $399 for Wegovy HD.[1]
- Mounjaro, cash: Lilly says to expect about the full retail price; the list price is $1,112.16 for 28 days.[2]
- Wegovy with commercial coverage: pay as little as $25 a month, with savings up to $100 a month.[1]
- Mounjaro with commercial coverage: pay as little as $25 if your plan covers it, or as low as $499 a month if it does not; the card ends December 31, 2026.[3]
See the Wegovy pill cost and Mounjaro cost guides for details.
Wegovy vs Mounjaro and Medicare
The Medicare GLP-1 Bridge covers Wegovy, injection or tablet, at $50 a month; Mounjaro is not on the list.[4] The Bridge runs July 1, 2026 through December 31, 2027.[8] People with type 2 diabetes are not eligible for the Bridge and should ask their Medicare drug plan, which may already cover a GLP-1 drug.[4]
Wegovy vs Mounjaro side effects
Reported in at least 5% of people in the label trials:
- Wegovy: nausea, diarrhea, vomiting, constipation, abdominal pain, abnormal skin sensations, headache, fatigue, indigestion, dizziness, bloating, burping, low blood sugar in people with type 2 diabetes, gas, gastroenteritis, acid reflux and hair loss.[5]
- Mounjaro: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain.[6]
Both carry a boxed warning about thyroid C-cell tumors in rodents and are not for people with a personal or family history of medullary thyroid cancer or MEN 2.[5][6]
Talk with a clinician
Which drug fits depends on whether you have type 2 diabetes, your other conditions and your coverage. Care Anytime members can reach state-licensed doctors by phone or video for non-emergency care through virtual physician access; we do not sell these drugs.
Frequently asked questions
Is Mounjaro or Wegovy better for weight loss?
Only Wegovy is approved for weight management. In its main trial, adults without diabetes lost an average 14.9% at 68 weeks on 2.4 mg against 2.4% on placebo. Mounjaro is approved for type 2 diabetes; its ingredient, tirzepatide, is sold for weight management as Zepbound. In the SURMOUNT-5 trial, tirzepatide averaged 20.2% weight loss against 13.7% for semaglutide. Talk with a clinician about which fits you.
Is Wegovy cheaper than Mounjaro?
Paying cash, yes: the Wegovy pill is $149 to $299 a month and the pen $199 to $399, while Mounjaro's list price is $1,112.16 for 28 days and Lilly posts no self-pay price. With commercial coverage, both savings offers let you pay as little as $25.
Can I take Mounjaro if I do not have diabetes?
Mounjaro is approved for adults and children 10 and older with type 2 diabetes, and its savings card requires a prescription for an FDA-approved use. Zepbound has the same ingredient and is approved for weight management. Your clinician decides what to prescribe.
Does Medicare cover Wegovy or Mounjaro?
The Medicare GLP-1 Bridge covers Wegovy, injection or tablet, for $50 a month for eligible enrollees from July 1, 2026 through December 31, 2027. Mounjaro is not on the Bridge; people with type 2 diabetes should ask their Medicare drug plan, which may already cover a GLP-1.
Can I switch from Wegovy to Mounjaro?
Only with your prescriber. Wegovy's label says not to use it with any other GLP-1 receptor agonist, and Mounjaro starts at 2.5 mg a week. Your clinician decides the timing and dose.
Related
Sources
- 1 Novo Nordisk NovoCare. Price your Wegovy: self-pay and savings offers for the pill and pen. Accessed Oct 30, 2026.
- 2 Eli Lilly and Company. Mounjaro frequently asked questions. Accessed Oct 30, 2026.
- 3 Eli Lilly and Company. Mounjaro savings and resources. Accessed Oct 30, 2026.
- 4 Medicare.gov. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (fact sheet, June 2026). Accessed Oct 30, 2026.
- 5 DailyMed (U.S. National Library of Medicine). Wegovy (semaglutide) injection and tablets: prescribing information. Accessed Oct 30, 2026.
- 6 DailyMed (U.S. National Library of Medicine). Mounjaro (tirzepatide) injection: prescribing information. Accessed Oct 30, 2026.
- 7 New England Journal of Medicine (abstract on PubMed). Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5), 2025. Accessed Oct 30, 2026.
- 8 Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Accessed Oct 30, 2026.